Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biotechnology company focused on neurodegenerative diseases, announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before expenses, according to a press release.
The net proceeds from the offering are intended to support continued clinical development of buntanetap, Annovis's lead drug candidate, for Alzheimer's disease (AD) and Parkinson's disease (PD), as well as for working capital and general corporate purposes. Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
This capital raise is critical for Annovis as it advances buntanetap through Phase 3 clinical trials. The company is headquartered in Malvern, Pennsylvania, and its stock trades on the New York Stock Exchange under the ticker ANVS. The offering provides the company with additional runway to generate data that could support regulatory filings and potential commercialization. For investors, the offering dilutes existing shareholders but also signals the company's commitment to advancing its pipeline. The warrants attached to the offering could provide additional capital if exercised.
This financing comes at a time when the Alzheimer's and Parkinson's treatment landscape is evolving, with a significant unmet need for disease-modifying therapies. Annovis's approach targeting multiple toxic proteins differentiates it from competitors focusing on single targets. The success of buntanetap in ongoing and future trials could have substantial implications for patients and the neurodegenerative disease market.
For more details, the full press release can be accessed at https://ibn.fm/KRpCW. Additional information about Annovis Bio is available on its website at www.annovisbio.com.
